Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Conlon Website

Kevin C. Conlon, M.D.

Selected Publications

1)  Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA.
Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
Blood. 121: 2029-37, 2013.
2)  Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC.
Phase 1 trial of IL-15 trans presentation blockade using humanized Mik├č1 mAb in patients with T-cell large granular lymphocytic leukemia.
Blood. 121: 476-84, 2013.
3)  Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM.
Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.
J. Immunother. 35: 629-40, 2012.
4)  Simone CB, Morris JC, Stewart DM, Urquhart NE, Janik JE, Kreitman RJ, Lita E, Conlon K, Wharfe G, Waldmann TA, Kaushal A.
Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma.
Blood. 120: 1816-9, 2012.
Click Here to View Collapsed Bibliography.

This page was last updated on 2/21/2014.